What's Happening?
Phlow Corp. has been selected for the FDA's National Priority Voucher Pilot Program to advance domestic manufacturing of ketamine, a critical medicine. The program aims to strengthen the U.S. pharmaceutical
supply chain and reduce dependence on foreign manufacturing. Phlow's project will establish a fully domestic supply chain for ketamine, addressing national health security concerns.
Why It's Important?
Phlow's participation in the FDA's pilot program highlights the importance of domestic pharmaceutical manufacturing in ensuring national health security. By establishing a U.S.-based supply chain for ketamine, Phlow is addressing critical shortages and reducing reliance on overseas sources. This initiative may lead to increased investment in domestic pharmaceutical production and innovation.